Nirmidas reaches a five-year product and service agreement with a CLIA lab to provide plasmonic pGOLD™ based diagnostic tests

On October 24th, 2018 Nirmidas reached a 5-year Product and Service Agreement with a LDT lab of a major healthcare provider in California, establishing partnership and collaboration with a highly reputable diagnostic lab with CLIA certificates to develop novel assays for clinical testing nationwide. Nirmidas will provide its innovative plasmonic gold (pGOLD™) near-infrared (NIR) fluorescence enhancing slides and OptiMidas™ assay system to develop and launch a next generation LDT serology clinical tests that could benefit millions of patients suffering from a range of infectious diseases in the United States.

 Multiplexed pGOLD™ assay platform: Based on fluorescence signal enhancing plasmonic gold slides, it is capable of multiplexed detection of a panel of viruses (up to 10 or more) with high performance. It uses 1-2 uL serum, plasma, or whole blood sample, or 200 uL saliva or urine sample. It offers dual channels fluorescence detection including near infra-red fluorescence for simultaneous detection of IgG/IgM antibodies from a single sample.

Multiplexed pGOLD™ assay platform: Based on fluorescence signal enhancing plasmonic gold slides, it is capable of multiplexed detection of a panel of viruses (up to 10 or more) with high performance. It uses 1-2 uL serum, plasma, or whole blood sample, or 200 uL saliva or urine sample. It offers dual channels fluorescence detection including near infra-red fluorescence for simultaneous detection of IgG/IgM antibodies from a single sample.

Nirmidas’ OptiMidas™ Multiplexed Assay Platform is an all-in-one system for multiplexed and dual channel bio-analyte NIR fluorescence detection. It combines plasmonic gold slides (pGOLD™ slides), MidaScan-IR™ or MidaScan™ Scanners to enable ELISA-like assay kits for multi-biomarker detection using minute amount of serological samples.  With significantly improved signal-to-noise ratio and wide dynamic range, the OptiMidas™ platform offers a multiplexed approach for LDT tests with high sensitivity and specificity.

The agreement reached is a testament of the importance of highly sensitive, specific and multiplexed assays benefiting patients and health care providers. The agreement was based on excellent assay performance obtained on pGOLD™ using hundreds of patient samples.

This agreement opens up an effective pathway for Nirmidas to bring its pGOLD™ assay platform to clinical lab testing in the US. This pathway is in addition to the FDA clearance pathway that Nirmidas has been pursuing for its Zika virus related serology assays.

 

About Nirmidas Biotech, Inc.

Nirmidas Biotech, Inc., provides solutions for bio-analytical diagnostics and in vivo imaging applications for life science applications using proprietary plasmonic gold (pGOLD™) microarray technology, near infra-red (NIR-II™) and infra-red fluorescence dyes that vastly enhances fluorescence signal, reduce background noise, optimized over a decade of research and innovation. Nirmidas’ products include pGOLD™ slides and dyes for fluorescence enhanced biological imaging and assays, and multiplexed ELISA like assay kits. Nirmidas’ platform technology enables new applications in diagnostics, imaging, and in drug development and therapeutics. Nirmidas is a member of the StartX community and the JLabs community. For more information, please visit: http://www.nirmidas.com.

 

About StartX

StartX is a 501(c)(3) Stanford-affiliated nonprofit in Silicon Valley that runs one of the world’s top startup accelerator programs. Our mission is to advance the development of the best entrepreneurs through experiential education and collective intelligence. Since launching in 2010, we have supported more than 160 companies and 370 entrepreneurs across a wide spectrum of industries. StartX and StartX Med, dedicated to medical and biotechnology, provides founders with access to a powerful network of entrepreneurs, investors, mentors, and industry partners, along with office space and a variety of other resources. We are supported by Stanford University, Stanford Hospital & Clinics, Kauffman Foundation, Microsoft, Steelcase, Intuit, Blackstone Charitable Foundation, Greylock Partners, Draper Fisher Jurvetson, Sequoia Capital, Merck, Genentech, Johnson & Johnson and many others. For more information, visit http://startx.stanford.edu.

 

About JLABS

JLABS, Johnson & Johnson Innovation, is a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers. More information: http://jlabs.jnjinnovation.com/